

TRANSCATHETER CLOSURE OF SEPTAL DEFECTS

Effective Date: January 1, 2018

Review Dates: 4/07, 4/08, 4/09, 4/10, 4/11, 4/12, 4/13,
5/14, 5/15, 5/16, 5/17, 5/18, 5/19

Date Of Origin: April 11, 2007

Status: Current

I. POLICY/CRITERIA

- A. Transcatheter closure of septal defects using FDA approved devices is covered for any of the following:
1. Secundum atrial septal defects (ASDs)
 2. Patent ductus arteriosus (PDA)
 3. Fenestration following a Fontan procedure
- B. Transcatheter closure of patent foramen ovale (PFO) is covered for associated cryptogenic stroke, transient ischemic attack, or arterial embolism due to presumed paradoxical embolism through the PFO, when conventional drug therapy (one or more antithrombotics) has failed. The device must be FDA approved (e.g. Amplatzer PFO Occluder) and used as labelled.
- C. Transcatheter closure of septal defects is not covered for all other indications including, but not limited to:
1. Ventricular septal defects
 2. When any of the following conditions are present:
 - Multiple defects that cannot be adequately covered by the device
 - Associated congenital cardiac anomalies that require cardiac surgery
 - Ostium primum atrial septal defects
 - Sinus venosus atrial septal defects
 - Partial anomalous pulmonary venous drainage
 - Pulmonary hypertension
 - Congestive heart failure
 - Sepsis
 - Coagulation disorders in patients who are unable to take antiplatelet or anticoagulant therapy
 3. Migraine prophylaxis
 4. Transmyocardial (perventricular) transcatheter closure of VSDs
 5. Obstructive Sleep Apnea

II. MEDICAL NECESSITY REVIEW

Required

Not Required

Not Applicable

III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- ❖ **POS:** *This policy applies to insured POS plans.*
- ❖ **PPO:** *This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.*
- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:** *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.*
- ❖ **MEDICAID/HEALTHY MICHIGAN PLAN:** *For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.*

IV. DESCRIPTION

Background

Transcatheter septal occlusion devices are implantable devices that are used to repair septal wall defects. Atrial or ventricular defects in the septal wall of the heart can have a number of adverse consequences, including abnormal ventricular volume load, ventricular pressure load, mixing of unoxygenated and oxygenated blood and inadequate systemic cardiac output. These abnormalities can lead to cardiac enlargement, pulmonary hypertension, rhythm disturbance, and stroke. Conventional open-heart surgical repair of septal defects carries some risk, especially in patients in whom heart or pulmonary function may be compromised. In addition, there is considerable morbidity associated with open-heart surgery. Moreover, some types of ventricular septal defects (VSDs) are difficult to repair surgically due to their location or orientation. Consequently, there has been considerable interest in the development of a transcatheter method of repairing septal lesions. Access to the defect is achieved through the venous system via the internal jugular vein or femoral vein in the groin.

V. CODING INFORMATION**ICD-10 Codes that may apply:**

G45.0 – G45.9 Transient cerebral ischemic attacks and related syndromes

I23.1 Atrial septal defect as current complication following acute myocardial infarction

I51.0 Cardiac septal defect, acquired

I63.9 Cerebral infarction, unspecified

Q21.1 Atrial septal defect

Q21.2 Atrioventricular septal defect

Q25.0 Patent ductus arteriosus

CPT Codes:

93580 Percutaneous transcatheter closure of congenital interatrial communication (i.e., Fontan fenestration, atrial septal defect) with implant

93582 Percutaneous transcatheter closure of patent ductus arteriosus

HCPCS Codes:

C1817 Septal defect implant system, intracardiac

C2628 Catheter, occlusion

Not Covered

93581 Percutaneous transcatheter closure of a congenital ventricular septal defect with implant

93799 Unlisted cardiovascular service or procedure (*for transcatheter ventricular septal defect procedure – explanatory notes must accompany claim*)

VI. REFERENCES

1. HAYES Medical Technology Directory, Transcatheter Closure of Septal Defects, Lansdale, PA: HAYES, Inc., February 12, 2002 and annual updates
2. Kapadia, S., Patent Foramen Ovale Closure: Historical Perspective, *Cardiology Clinics*, Vol. 23, 73-83, 2005.
3. Latson, L., Jones, T., et al., Analysis of Factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder, *American Heart Journal*, Vol. 151, Issue 5, 1136.e7-1136.e11, May 2006.
4. Rome, J., and J. Kreutzer, Pediatric interventional catheterization: reasonable expectations and outcomes, *Pediatric Clinics of North America*, Vol. 51, Issue 6, 1589-1610, December 2004.
5. Wang, J., Shen, T., et al., Short- and intermediate-term results of transcatheter closure of atrial septal defect with the Amplatzer Septal Occluder, *American Heart Journal*, 511-517, September 2004.

6. Wisconsin Physicians Service (WPS), Intraoperative Transesophageal Echocardiography, Local Coverage Decision (LCD) CV-034, Original effective date: 01/15/2002, Revision date: 10/01/2005.
7. Wisconsin Physicians Service (WPS), Medical Devices, Local Coverage Decision (LCD), PHY 067, Original effective date: 09/01/1996, Revision date: 01/01/2005.
8. Wisconsin Physicians Service (WPS), Transesophageal Echocardiography, Local Coverage Decision (LCD) CV-007, Original effective date: 02/15/1996, Revision date: 10/01/2005.
9. Carminati, M., Butera, G., et al., Transcatheter Closure of Congenital Ventricular Septal Defect with Amplatzer Septal Occluders, American Journal of Cardiology, Vol. 96, Issue 12, suppl, 52L-58L, Dec 19, 2005
10. Transcatheter Closure of Septal Defects, Aetna Clinical Policy Bulletin, April 2007. Available on the World Wide Web @ http://www.aetna.com/cpb/cpb_alpha.html (Retrieved March 27, 2008; March 16, 2009; February 24, 2010; March 16, 2011; March 12, 2012; March 5, 2013; April 8, 2014; April 20, 2015; April 14, 2016; March 23, 2017; April 6, 2018 March 25, 2019)
11. Transcatheter Closure of Cardiovascular Defects, Cigna Healthcare Coverage Position, November 2007. Available on the World Wide Web @ http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0011_coveragepositioncriteria_transcatheter_closure_septal_defects_PFO.pdf (Retrieved March 27, 2008, March 16, 2009, February 24, 2010, March 12, 2012, March 5, 2013, April 8, 2014, April 20, 2015, April 14, 2016, March 23, 2017 & April 6, 2018) https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm_0011_coveragepositioncriteria_transcatheter_closure_septal_defects_pfo.pdf (Retrieved March 25, 2019).
12. Closure Devices for Patent Foramen Ovale and Atrial Septal Defects, The Regence Group, February 2006. Available on the World Wide Web @ <http://www.regence.com/trgmedpol/surgery/sur105.html> (Retrieved March 27, 2008 & February 24, 2010)
13. Hayes, Inc. Transcatheter closure of Ventricular Septal Defects, July, 2008 and annual updates.
14. Johnston, S. C. Patent Foramen Ovale Closure — Closing the Door Except for Trials N Engl J Med 2012; 366:1048-1050
15. Furlan, A. J., Reisman, M. et.al. for the CLOSURE I Investigators. Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale. N Engl J Med 2012; 366:991-999
16. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Juni P; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013 Mar 21;368(12):1083-91.
17. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen

- ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013 Mar 21;368(12):1092-100.
18. Messé SR, Kent DM. Still no closure on the question of PFO closure. N Engl J Med. 2013 Mar 21;368(12):1152-3.
 19. Hayes, Inc. Transcatheter Closure of Patent Foramen Ovale for Prevention of Stroke, January 8, 2015
 20. US Food and Drug Administration , Amplatzer PFO Occluder @ <https://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm526921.htm> (Accessed March 23, 2017)

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.